These experimental data combined with our in silico modeling and epidemiologic data strongly suggest a role for DYRK2 in NB tumorigenesis and the potential for harmine as an effective treatment option for MYCN-amplified NB. This evidence concerns the gene DYRK2 and neuroblastoma.